HIGH VERSUS STANDARD DOSES OF CORTICOSTEROIDS IN COVID-19 PATIENTS WITH AN ACUTE RESPIRATORY DISTRESS SYNDROME: a controlled observational comparative study
ABSTRACT INTRODUCTION Despite the increasing evidence of the benefit of corticosteroids for the treatment of moderate-severe Coronavirus disease 2019 (COVID-19) patients, no data are available about the potential role of high doses of steroids for these patients.METHODS All consecutive confirmed COVID-19 patients admitted to a single center were selected, including those treated with steroids and an acute respiratory distress syndrome (ARDS). Patients were allocated to the high doses (HD, ≥250mg/day of methylprednisolone) of corticosteroids or the standard doses (SD, ≤1.5mg/kg/day of methylprednisolone) at discretion of treating physician. The primary endpoint was the mortality between both cohorts and secondary endpoints were the risk of need for mechanical ventilation (MV) or death and the risk of developing a severe ARDS.RESULTS 573 patients were included: 428 (74.7%) men, with a median (IQR) age of 64 (54–73) years. In HD cohort, a worse baseline respiratory situation was observed and male sex, older age and comorbidities were significantly more common. After adjusting by baseline characteristics, HD were associated with a higher mortality than SD (adjusted-OR 2.46, 95% CI 1.58 – 3.83, p<0.001) and with an increased risk of needing MV or death (adjusted-OR 2.50, p=0.001). Conversely, the risk of developing a severe ARDS was similar between groups. Interaction analysis showed that HD increased mortality exclusively in elderly patients.CONCLUSION Our real-world experience advises against exceeding 1-1.5mg/kg/day of corticosteroids for severe COVID-19 with an ARDS, especially in older subjects. This reinforces the rationale of modulating rather than suppressing immune responses in these patients.SUMMARY In patients with severe COVID-19, high doses of corticosteroids are associated with a higher mortality and risk of need for mechanical ventilation or death compared to standard doses. This deleterious effect is mainly observed in the elderly..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 15. Jan. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Monreal, Enric [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2020.07.17.20156315 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI01836697X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI01836697X | ||
| 003 | DE-627 | ||
| 005 | 20230429100023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200721s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.07.17.20156315 |2 doi | |
| 035 | |a (DE-627)XBI01836697X | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.07.17.20156315 | ||
| 035 | |a (biorXiv)10.1101/2020.07.17.20156315 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Monreal, Enric |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HIGH VERSUS STANDARD DOSES OF CORTICOSTEROIDS IN COVID-19 PATIENTS WITH AN ACUTE RESPIRATORY DISTRESS SYNDROME: a controlled observational comparative study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT INTRODUCTION Despite the increasing evidence of the benefit of corticosteroids for the treatment of moderate-severe Coronavirus disease 2019 (COVID-19) patients, no data are available about the potential role of high doses of steroids for these patients.METHODS All consecutive confirmed COVID-19 patients admitted to a single center were selected, including those treated with steroids and an acute respiratory distress syndrome (ARDS). Patients were allocated to the high doses (HD, ≥250mg/day of methylprednisolone) of corticosteroids or the standard doses (SD, ≤1.5mg/kg/day of methylprednisolone) at discretion of treating physician. The primary endpoint was the mortality between both cohorts and secondary endpoints were the risk of need for mechanical ventilation (MV) or death and the risk of developing a severe ARDS.RESULTS 573 patients were included: 428 (74.7%) men, with a median (IQR) age of 64 (54–73) years. In HD cohort, a worse baseline respiratory situation was observed and male sex, older age and comorbidities were significantly more common. After adjusting by baseline characteristics, HD were associated with a higher mortality than SD (adjusted-OR 2.46, 95% CI 1.58 – 3.83, p<0.001) and with an increased risk of needing MV or death (adjusted-OR 2.50, p=0.001). Conversely, the risk of developing a severe ARDS was similar between groups. Interaction analysis showed that HD increased mortality exclusively in elderly patients.CONCLUSION Our real-world experience advises against exceeding 1-1.5mg/kg/day of corticosteroids for severe COVID-19 with an ARDS, especially in older subjects. This reinforces the rationale of modulating rather than suppressing immune responses in these patients.SUMMARY In patients with severe COVID-19, high doses of corticosteroids are associated with a higher mortality and risk of need for mechanical ventilation or death compared to standard doses. This deleterious effect is mainly observed in the elderly. | ||
| 700 | 1 | |a de la Maza, Susana Sainz |e verfasserin |4 aut | |
| 700 | 1 | |a Natera-Villalba, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Beltrán-Corbellini, Álvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Jorge, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Velasco, Jose Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Walo-Delgado, Paulette |e verfasserin |4 aut | |
| 700 | 1 | |a Muriel, Alfonso |e verfasserin |4 aut | |
| 700 | 1 | |a Zamora, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso-Canovas, Araceli |e verfasserin |4 aut | |
| 700 | 1 | |a Fortún, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Manzano, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Montero-Errasquín, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Costa-Frossard, Lucienne |e verfasserin |4 aut | |
| 700 | 1 | |a Masjuan, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a María Villar, Luisa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 15. Jan. |
| 773 | 1 | 8 | |g year:2021 |g day:15 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.07.17.20156315 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 15 |c 01 | ||
| 953 | |2 045F |a 570 | ||